Research status of nano-drugs in the treatment of non-alcoholic fatty liver disease
10.13699/j.cnki.1001-6821.2024.23.024
- VernacularTitle:纳米药物在非酒精性脂肪性肝病治疗中的研究现状
- Author:
Wei-an QIU
1
;
Bo ZHANG
;
Yu-yan ZHANG
;
Yu ZHU
;
Wei GUO
;
Yue LIU
;
Yong YE
Author Information
1. 广西医科大学药学院,广西壮族自治区南宁 530021
- Publication Type:Journal Article
- Keywords:
nano-drug;
non-alcoholic fatty liver disease;
drug therapy;
drug delivery;
drug carrier
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(23):3482-3486
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease(NAFLD)has become one of the most common liver diseases in the world.Its pathogenesis is complex,and the current treatment strategies still cannot completely reverse the progression of NAFLD.In recent years,with the continuous development of nanotechnology and nanomedicine,nano-drugs is gradually becoming a new strategy for the treatment of NAFLD due to its safety,stability,slow release and targeting characteristics.At present,the main focus of nano-drugs on the mechanism of NAFLD is lipid metabolism,insulin resistance and oxidative stress,and few studies have been conducted to engineer nano-drugs by combining different targets and signaling pathways in the pathogenesis of NAFLD.This review focuses on the treatment of liver diseases,and summarizes and expounds the therapeutic research on NAFLD surrounding nano-drugs systems,including nanocrystals,lipid nanoparticles,polymer nanoparticles,micelles,etc.,in order to provide certain ideas and guidance for relevant experimental research and drug development in this field.
